778576-62-8 Usage
General Description
Oglemilast is a selective phosphodiesterase 4 (PDE4) inhibitor that has been studied for its potential as a treatment for chronic obstructive pulmonary disease (COPD) and other inflammatory conditions. By inhibiting PDE4, oglemilast can increase levels of cyclic adenosine monophosphate (cAMP), which plays a role in regulating inflammation and immune responses in the body. This mechanism of action makes oglemilast a promising candidate for reducing airway inflammation and improving lung function in COPD patients. Clinical trials have shown that oglemilast may have the potential to be an effective and well-tolerated treatment for COPD, although further research is ongoing to fully understand its safety and efficacy.
Check Digit Verification of cas no
The CAS Registry Mumber 778576-62-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,7,8,5,7 and 6 respectively; the second part has 2 digits, 6 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 778576-62:
(8*7)+(7*7)+(6*8)+(5*5)+(4*7)+(3*6)+(2*6)+(1*2)=238
238 % 10 = 8
So 778576-62-8 is a valid CAS Registry Number.
778576-62-8Relevant articles and documents
SYNTHESIS OF HETEROCYCLIC COMPOUNDS
-
Page/Page column 8, (2008/06/13)
Methods for the synthesis of heterocyclic compounds including N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-methanesulfonamido-dibenzo[b,d]furan-1-carboxamide and pharmaceutically acceptable salts thereof.
NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
-
Page 68, (2008/06/13)
The present invention relates to novel heterocyclic compounds, their analogs, their tautomers, their regioisomers, their stereoisomers, their enantiomers, their diastereomers, their polymorphs, their pharmaceutically acceptable salts, their appropriate N-
